| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66bce9cb071741961f540cff6c647803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d93a3fdd031e483c033ce2641aca024b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b26652f606ab3aded18dee37f1efa504
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7b56f8e9a6b41d26bfb8f3da696c09d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2cf5e32b0279eaf5ffc04736145e96c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b9ecd28810db421823f637142302487
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44508cceb8bc6645264b0d5e115dfde7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10121
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| filingDate |
2005-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04152af900337c32a1d4c17f9c107840
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0c54b341eba8a6a80707718357189e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ee312f824d60ad23dfcd3fdbe593b52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f64727c2c1abb41445f5404b660e8fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29d0b1b7bf6f771ed33780ffc6d060f9 |
| publicationDate |
2006-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006039739-A1 |
| titleOfInvention |
Hepatitis b viral (hbv) mutants detection and application |
| abstract |
The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular one or more nucleoside or nucleotide analogs and/or non-nucleoside or non-nucleotide agents. More particularly, the present invention is directed to hepatitis B (HBV) variants RTh234Y and preS1 191V which correlate with a higher risk of an adverse disease outcome and exhibiting complete or partial resistance to abacavir (ABC) and lamividuine (LMV). The present invention further contemplates assays for detecting such viral variants which assays are useful in diagnosing a higher risk of an adverse disease outcome, in monitoring antiviral therapeutic regimes and in developing new or modified nucleoside or nucleotide analogs or non-nucleoside or non-nucleotide agents. The present invention also contemplates the use of viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus. Such agents are useful in treating hepatitis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2057268-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9677076-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2057268-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9034841-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9127278-B2 |
| priorityDate |
2004-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |